Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been assigned an average rating of “Buy” from the thirteen analysts that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $31.13.
HRTX has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Monday, September 25th. Mizuho initiated coverage on shares of Heron Therapeutics in a research report on Tuesday, September 26th. They issued a “buy” rating and a $28.00 price objective for the company. Northland Securities initiated coverage on shares of Heron Therapeutics in a research report on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 price objective for the company. Noble Financial reiterated a “buy” rating and issued a $24.00 price objective on shares of Heron Therapeutics in a research report on Friday, October 6th. Finally, Oppenheimer initiated coverage on shares of Heron Therapeutics in a research report on Monday, October 30th. They issued a “buy” rating and a $27.00 price objective for the company.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the transaction, the vice president now owns 7,584 shares in the company, valued at $151,680. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 19.93% of the company’s stock.
Heron Therapeutics (NASDAQ HRTX) traded up $0.30 during trading hours on Friday, reaching $23.20. 915,369 shares of the company’s stock traded hands, compared to its average volume of 1,120,538. Heron Therapeutics has a one year low of $12.25 and a one year high of $23.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. The stock has a market capitalization of $1,260.00, a price-to-earnings ratio of -6.12 and a beta of 2.12.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The company had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. research analysts predict that Heron Therapeutics will post -3.38 EPS for the current year.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.